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ABSTRACT
The myeloproliferative neoplasms are chronic myeloid cancers divided in 
Philadelphia positive (Ph+), chronic myeloid leukemia, or negative: polycythemia 
vera (PV) essential thrombocythemia (ET), and primary myelofibrosis (PMF). Most 
Ph negative cases have an activating JAK2 or MPL mutation. Recently, somatic 
mutations in the calreticulin gene (CALR) were detected in 56–88% of JAK2/MPL-
negative patients affected by ET or PMF. The most frequent mutations in CARL gene 
are type-1 and 2. Currently, CALR mutations are evaluated by sanger sequencing. The 
evaluation of CARL mutations increases the diagnostic accuracy in patients without 
other molecular markers and could represent a new therapeutic target for molecular 
drugs.
We developed a novel detection assay in order to identify type-1 and 2 
CALR mutations by PNA directed PCR clamping. Seventy-five patients affected by 
myeloproliferative neoplasms and seven controls were examined by direct DNA 
sequencing and by PNA directed PCR clamping. The assay resulted to be more 
sensitive, specific and cheaper than sanger sequencing and it could be applied even 
in laboratory not equipped for more sophisticated analysis. Interestingly, we report 
here a case carrying both type 1 and type2  mutations in CALR gene.
INTRODUCTION
The myeloproliferative neoplasms (MPN) are chronic 
myeloid cancers characterized by the overproduction of 
mature blood cells and risk of transformation into acute 
myeloid leukaemia (AML) [1, 2]. In addition to chronic 
myeloid leukaemia (CML) characterized by the BCR-ABL 
fusion gene, the three most common myeloproliferative 
neoplasms are essential thrombocythemia (ET), 
polycythemia vera (PV), and primary myelofibrosis (PMF). 
In 2005 the JAK2 V617F mutation has been identified in 
patients with PV, ET and PMF [3, 4]. Mutations of JAK2 
exon 12 [5, 6] and MPL exon 10 [7] were subsequently 
detected in a subsets of patients. Recently, several studies 
identified additional mutations present in smaller fraction 
of patients [8–12]. In 2013, somatic mutations in the CALR 
gene, encoding calreticulin, were detected in most patients 
with ET or PMF without mutations in JAK2 and MPL 
genes [13, 14]. 
Calreticulin is a protein with different functions. In 
the endoplasmic reticulum the protein modulates calcium 
homeostasis and regulates the folding of glycoproteins. [15] 
Calreticulin is also localized in other cellular compartments 
where it regulates many biological functions including 
apoptosis and proliferation. [16]. All mutant CALR proteins 
discovered until now share a novel amino acid sequence at 
the C-terminal. The non-mutant CALR C-terminal is mainly 
negatively charged, whereas the mutant CALR C-terminal 
is largely positively charged [17].The mutant CALR 
protein lacks the endoplasmic reticulum retention signal 
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(KDEL) and therefore it may have an altered subcellular 
localization.  The role of CALR in the pathogenesis of MPN 
is largely unknown. Klampfl and colleagues and Nangalia 
and colleagues [13, 14] elegantly demonstrated that CALR 
mutations are acquired early in the major clone.  Several 
studies are trying to shed light on how mutant CALR can 
sustain the uncontrolled proliferation. It was demonstrated 
that mutant CALR activates JAK/STAT signaling thus 
generating a proliferative signaling [13, 14]. Recently, it 
was shown that the forced expression of mutant CALR 
in hematopoietic cell lines resulted in MPL-dependent 
activation of MAPK signaling. In line whit this finding, 
patients with CALR mutations showed increased MAPK 
activity in blood cells and in CD34+ cells leading to 
enhance megakaryopoiesis and pro-platelet production. 
[18] Recently it was also shown the IL3 independent 
growth of CALR mutant cells [17].
CALR mutations have been reported as mutually 
exclusive with JAK2 and MPL mutations and are present 
in a percentage of patients ranging from 56 to 88% 
of JAK2/MPL-negative cases [13, 14]. A recent paper 
reported a patient who carried simultaneously both 
mutations, JAK2 V617F and CALR exon 9 [19]. Many 
different CALR mutations have been described in exon 
9 but the most frequent is type-1 [L367fs*46; deletion of 
52 base pairs (bp)] and type-2 [K385fs*47; insertion of 
5 bp] [13, 14]. Currently, the method commonly exploited 
for the detection of CARL mutations is sanger sequencing. 
Peptide nucleic acid (PNA) is able to hybridize 
very specifically to DNA. It is recognized that the 
binding PNA/DNA is more stable than DNA/DNA 
or DNA/RNA duplexes [20, 21], but PNA sequences 
cannot be extended by polymerase [22]. Consequently, 
PNA/DNA duplex suppresses DNA amplification.  This 
is the principle that allowed to design PNA directed 
PCR clamping to discriminate wild type from mutated 
sequences [22–24].
The goal of the study was to make the diagnosis of 
CALR mutations more rapid, easy and accessible.
Based on this premise, we developed a novel and 
sensitive assay based on PNA directed PCR clamping for 
the detection of CALR mutations (type-1 and type-2) in 
MPN patients. 
RESULTS 
As show in Figure 1, the method described here 
forecasts that both PNA probe and PCR primer competitor 
target sites overlap, thus leading to a direct competition 
towards complementary DNA. In case CALR sequence 
is wild type, a perfect matching occurs between PNA 
(designed on wild sequence) and DNA. As a consequence, 
the PNA-template hybridization is favoured and DNA 
amplification is strongly suppressed. This occurs in patients 
with CALR wild-type (WT) or CALR type-1 mutation 
(DEL), producing weak bands at different lengths. 
Figure 1: Step II: PNA clamping experimental design. Template amplification of CALR wild-type (WT), type-1 (DEL) and type-2 
(INS) mutations (A) in absence of PNA probe (B) and with PNA probe. Perfect PNA/DNA hybridization occurs when CALR template 
sequence is wild-type (WT) or type-1 mutation (DEL, indicated by [¨¨]), thus leading to a significant reduction of PCR amplification. 
By contrast, in presence of type-2 mutation (INS, indicated by +++++), PNA/DNA duplex is highly destabilized, on behalf of primer 
Competitor Rev, allowing strong template amplification. 
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The lengths of the bands allow to distinguish 
between CALR WT and DEL (Figure 2B). Conversely, 
a non-perfect matching ( as in case of a mutation) 
destabilizes the PNA hybridization thus favouring the 
hybridization between template and primer competitor. In 
this case an amplification product is evident. (as in the case 
of patients with CALR type-2 mutation (INS)) (Figure 2B).
There are two PCR steps. Through the first step, the 
selected CALR sequence is amplified (Figure 2A). The 
second step is carried-out in duplicate, in the presence (+) 
or in the absence (-) of the PNA probe. The final result 
should be interpreted by reading the double loading for 
each individual patient (Figure 2B).
As shown in Figure 2B a non-specific band appears 
in patients approximately 100 bp higher than the WT 
band; however, it will not compromise the interpretation 
of the result. As shown in Figure 3, sensitivity was 
assessed mixing, at different ratio, mutated (type-1 and 
type-2) and WT template. Dilutions were as follow: 100, 
50, 20, 10, and 5 % type-1 deletion (52 bp) mutated versus 
WT template and 100, 50, 20, 10, 5, 1, 0.1, 0.01, 0.001% 
type-2 insertion (5 bp) mutated versus WT template. 
The method displays a quite high sensitivity, allowing to 
detect an amount of mutated template as low as 10% for 
CALR type-1 and 0,1% for CALR type-2 mutations, which 
cannot be identified by sanger sequencing. Our diagnostic 
test shows a sensitivity of 100% (CI 79.41% to 100.00%) 
and a specificity of 98,5% (CI 91.96% to 99.96%) with an 
AUC corresponding to 0.99. 
Seventy-five patients affected by MPN and seven 
controls were examined in double blind either by direct 
DNA sequencing or by PNA directed PCR clamping, 
displaying identical readout except for two samples: 
mutated (type-1 mutation) in PNA directed PCR clamping, 
but wild-type by sanger sequencing. For these patients, 
the experiment was repeated and the shorter bands, 
resulting by step II of PNA directed PCR clamping, were 
purified and cloned in pGEM-T Easy Vector as previously 
described. Then, they were sequenced by sanger method 
using T7 and SP6 primers (respectively #Q5021 e #Q5011, 
Promega, Milan, Italy): one of these resulted wild-type 
and represents the only false positive sample tested; 
unexpectedly, the second one was found to have both the 
CALR type-1 and 2 mutations (Figure 4).
DISCUSSION
The majority of Ph- myeloproliferative neoplasms 
shows mutations in JAK2 or MPL genes. Recently, 
additional mutations were identified in ET and PMF 
wild-type for JAK2 and MPL. We developed a novel 
molecular assay, based on PNA direct PCR clamping, 
for a rapid diagnosis of CALR type-1 and 2 mutations 
in patients affected by MPN. The assay shows high 
efficiency, sensitivity and specificity. Our method appears 
to be faster, cheaper and easily interpretable compared 
with DNA sanger sequencing, the method most commonly 
used for the detections of these mutations. In clinical 
Figure 2: Detection analysis by PNA directed PCR clamping of CALR type-1 (DEL) and type-2 (INS) mutations. 
(A) Step I: cDNA amplification of patients with CALR wild-type (WT), type-1 (DEL) and type-2 (INS) mutations. pGEM-T-CALR wild-type 
(WT), pGEM-T-CALR type-1 mut (DEL), pGEM-T-CALR type-1 mut 50% vs. wild-type (DEL 50%) and pGEM-CALR type-2 mut (INS) 
were used as PCR positive control. 5 µL of each amplifier were loaded on 1% Agarose-TBE 1x gel with 5 µg/mL ethidium bromide (EtBr) 
and run at 120 V for 30 minutes. (B) Step II: PCR amplification of a small area of CALR gene, containing type-1 and type-2 mutations, was 
carried-out in absence (−) or in presence (+) of PNA probe. The plasmids amplified in the step I were used, in a dilution of 1:100, in the step 
II in order to interpret the results, 10 µL of each amplifier were loaded on 2% Agarose-TBE 1x gel with 5µg/mL EtBr and run at 100 V for 
30 minutes and than at 65 V for 15 minutes. The arrow indicates the non-specific band present in the amplified of patients.
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practice, the evaluation of CARL mutations increases the 
diagnostic accuracy of ET and PMF and allows a more 
accurate diagnosis in patients without other molecular 
markers. Greater accuracy of diagnosis can result in 
a more precise prediction of prognosis and in a more 
effective therapeutic choice [25, 26]. Furthermore, the 
mutated protein CALR could represent a new therapeutic 
target for molecular drugs [25]. Contrary to JAK2 V617F 
mutation, a correlation between CALR mutant allele 
quantification and clinical presentation has not yet been 
demonstrated [27]. Despite the sanger sequencing is the 
most commonly method used to diagnose these mutations, 
many laboratories in the world are not equipped with 
such a facility or cannot effort the cost of this procedure. 
In conclusion, considering the diagnostic relevance of 
the CALR mutations, the PNA direct PCR clamping 
assay might represent a good alternative method for the 
detection of CALR type-1 and type-2 mutations, especially 
considering the costs and the lower sensitivity of the DNA 
sequencing method. Furthermore, because this assay is 
faster, more sensitive, and less expensive than sanger 
sequencing, it might be applied also in laboratory not 
equipped for sophisticated analysis, reducing costs and 
time for an advanced molecular diagnosis.
Figure 4: Sequencing chromatogram of patient with both CARL type-1 and 2 mutations compared with WT sequence. 
CALR type-1 mutation is indicated in blue, while CALR type-2 is highlighted in red.
Figure 3: PNA directed PCR clamping sensitivity was assessed mixing, at different ratio, mutated (type-1 and type-2) 
and WT template. The arrows indicate the sensitivity of the method. (A) Dilutions were as follow: 100, 50, 20, 10, 5, 1% CALR type-1 
mutation vs. WT template and (B) 100, 50, 20, 10, 5, 1, 0,1, 0,01, 0,001% CARL type-2 mutation vs. WT template. The dashed vertical bar 
separates different parts of the same gel. 
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MATERIALS AND METHODS
Cells sources and RNA extraction
After informed consent, peripheral blood were 
collected at diagnosis from 82 patients: 75 patients 
affected by myeloproliferative disease and 7 controls (5 
healthy donors and 2 patients affected by myelodysplastic 
syndromes). The study was approved by the ethic 
committee on December 16th 2015 (number of approval 
212/2015). Table 1 summarizes clinical and molecular 
characteristics of patients. 
Total RNA was extracted from buffy-coat fraction 
using TRIzol Reagent (Ambion, Thermo Fisher Scientific, 
Massachusetts, USA), following the manufacturer’s 
instructions, and 1 µg was reverse transcribed using 
random hexamers as primers in a final volume of 25 µL.
Cloning PCR controls with pGEM®-T easy 
vector
CALR WT, CALR DEL and CALR INS were 
amplified and purified by QIAgenquick Gel Extraction 
Kit (Qiagen, Hildem, Germany) and cloned in pGEM-T 
Easy Vector (Promega, Milan, Italy). All reactions were 
performed following the manufacturer’s instructions. 
Plasmids were used as positive control in PCR steps. 
Primers sequences are listed in Table 2.
Capillary sanger sequence method for the 
detection of CALR
Detection of CALR mutations was performed by 
capillary sanger sequence method. DNA was extracted 
by Maxwell 16 (Promega, Milan, Italy) following the 
manufacturer’s protocol. CALR was amplified and 
analyzed by sequencing with BigDye terminator v3.1 
(Applied Biosystem, Foster City, California) and capillary 
electrophoresis on ABI PRISM 3130XL (Applied 
Biosystem, Foster City, California). Primers sequences are 
listed in Table 2. The sensitivity was previously estimated 
by serial dilutions experiments to be 20%.
PNA directed PCR clamping 
Step I: 3 μL of cDNA were used to amplify the 
CALR mRNA sequence (acc. # NM_004343) and ~10 ng 
of pGEM-T-CALR wild-type (WT), pGEM-T-CALR type-1 
mut (DEL), pGEM-T-CALR type-1 mut 50% vs. wild-type 
(DEL 50%) and pGEM-CALR type-2 mut (INS) were used 
as PCR positive control. 
Primers sequences were as follow (step I):
Fwd: 5'–ATGCTGCTATCCGTGCCGCTGCT–3'  
Rev: 5'–TCAGGCCTCAGTCCAGCCCTGGA–3'
Reaction volume was 50 μL and the final 
concentrations of the reagents were the following: MgCl2 
[2, 5 μM], 10X PCR Buffer [1X], dNTPs [0,4 μM], 
AmpliTaq 2U, Primers [0, 6 μM], DMSO 10% , H2O 
MilliQ.
Step II: 1µL of  step I PCR product was used to 
amplify a small area of CALR gene, containing type-1 
and type-2 mutations. PCR amplification was carried-out 
in absence (−) or in presence (+) of PNA probe, at a 
concentration 6 × greater than primer Competitor Rev. The 
amplification performed without (−) PNA probe represents 
an internal positive control displaying the PCR efficiency.
Primers and PNA probe sequences were as follow 
(step II):
Fwd: 5'–CCTCTGGCAGGTCAAGTCTG–3'
Rev Competitor: 5'– ATCCTCCGACAATTGTCCT 
CTG–3'
PNA probe: 5'–OO–CATCCTCCTTGTCCTC–3'
Reaction volume was 50 μL and he final 
concentrations of the reagents were the following:
Table 1: Clinical and molecular characteristics of patients
Disease n° of pts % of JAK2 mut pts % of CALR mut pts
PV 25 28 8
ET 38 13 40
PMF 12 17 25
Controls 7 0 0
PV: polycythemia vera; ET: essential thrombocythemia; PMF: primary myelofibrosis
Table 2: Primers sequences used for cloning and for sanger sequencing
Cloning CALR Fwd 5'–ATGCTGCTATCCGTGCCGCTGCT–3'
CALR Rev WT 5'–CTACAGCTCGTCCTTGGCCTGGC–3'
CALR Rev Mut 5'–TCAGGCCTCAGTCCAGCCCTGGA–3'
Sequencing CALR Fwd 5'–ACAACTTCCTCATCACCAACG–3'
CALR Rev 5'–GGCCTCAGTCCAGCCCTG–3'
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MgCl2 [1, 25 μM], 10X PCR Buffer [1X], dNTPs 
[0, 2 μM], AmpliTaq 1U, Primers [0, 2 μM], PNA probe 
[1, 2 μM].
PNA probe, designed on the human CALR cDNA 
(acc. # NM_004343), encompasses a very short sequence 
in exon 9, common to both the wild-type and type-1 
mutation sequence. PNA-PCR clamping conditions for 
CALR mutations detection were as follow: step I PCR: 
94°C 3 min, (94°C 30 s,  65°C 40 s, 72°C 1 min 30 s) for 
35 cycles, 72°C 5 min; step II PCR: 94°C 3 min, (94°C 
30 s, 55°C 27 s, 72°C 45 s) for 30 cycles. 
Diagnostic test valuation with a confidence interval 
(CI) of 95% and the area under the curve (AUC) were 
calculated with MedCalc software (MedCalc, Osten, 
Belgium).
The second step of this assay has been patented by 
the authors and by the University of Turin (patent pending, 
number 102016000042586) 
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